Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Refractory Myasthenia Gravis
NCT00619671Phase 2Completed
- Sponsor
- The University of Vermont
- Start
- Apr 2004
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in myasthenia gravis (MG), sponsored by The University of Vermont. Started Apr 2004; status: completed.
02
Drugs
rituximab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT00619671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00619671.